The epidermal repopulation of Langerhans cells (LCs) during wound healing was examined using a human skin severe combined immunodeficient (SCID) mouse model. The experiments, were carried out after proving the human origin of keratinocytes repopulating the wound beds using the W6/32 monoclonal antibody. It was shown that CD1a- and HLA-DR-positive dendritic cells (mostly LCs) are already detectable 2 days after injury within the newly formed epithelium. In the excisional wounds investigated, neither HLA-DR nor ICAM-1 expression of human keratinocytes was observed. Our present data suggest that LC repopulation is an early event in the process of re-epithelization.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0165-2478(96)02596-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Monocytes give rise to Langerhans cells that preferentially migrate to lymph nodes at steady state.
Proc Natl Acad Sci U S A
November 2024
Microbiology and Immunology Department, Stanford University School of Medicine, Stanford, CA 94305.
Current evidence suggests that ontogeny may account for the functional heterogeneity of some tissue macrophages, but not others. Here, we asked whether developmental origin drives different functions of skin Langerhans cells (LCs), an embryo-derived mononuclear phagocyte with features of both tissue macrophages and dendritic cells. Using time-course analyses, bone marrow chimeras, and fate tracing models, we found that the complete elimination of embryo-derived LCs at steady state results in their repopulation from circulating monocytes.
View Article and Find Full Text PDFEpithelial RANKL Limits Experimental Periodontitis via Langerhans Cells.
J Dent Res
November 2024
Institute of Biomedical and Oral Research, Faculty of Dental Medicine, Hebrew University, Jerusalem, Israel.
Article Synopsis
- - RANKL is identified as a key player in periodontitis, primarily influencing osteoclast differentiation and acting as a link between bone and the immune system, showcasing a complex role beyond its initial recognition as an activator of dendritic cells (DCs).
- - In studies using ligature-induced periodontitis (LIP), rapid bone loss was observed, which eventually stopped despite the presence of the ligature, indicating a connection to immunosuppressive conditions in the gingiva associated with T regulatory (Treg) cell expansion.
- - Experiments with K14-RANKL mice, which overexpress RANKL in gingival cells, revealed that increased RANKL leads to a favorable balance of immune cells
Adipose tissue-derived mesenchymal stem cells promote the vascularization of pancreatic islets transplanted into decellularized pancreatic skeletons.
Transpl Immunol
October 2024
Laboratory of Pancreatic Islets, Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague, Czech Republic; Diabetes Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague, Czech Republic. Electronic address:
We have recently developed a model of pancreatic islet transplantation into a decellularized pancreatic tail in rats. As the pancreatic skeletons completely lack endothelial cells, we investigated the effect of co-transplantation of mesenchymal stem cells and endothelial cells to promote revascularization. Decellularized matrix of the pancreatic tail was prepared by perfusion with Triton X-100, sodium dodecyl sulfate and DNase solution.
View Article and Find Full Text PDFPeroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity.
Front Oncol
January 2024
Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
Article Synopsis
- A series of seven clinical trials explored if manipulating ligand-receptor interactions in tumors could make cancer treatment more effective, focusing on relapsed or refractory metastatic neoplasias.
- Different combinations of pioglitazone, a drug that activates specific receptors, with various transcriptional modulators and low-dose chemotherapy showed promise in reprogramming cancer characteristics, leading to tumor cell death and improved disease control across several cancer types.
- The research suggests that pioglitazone can be a key drug in innovative treatment strategies by harnessing tumor plasticity and enhancing the effects of existing therapies.
Addressing Genetic Tumor Heterogeneity, Post-Therapy Metastatic Spread, Cancer Repopulation, and Development of Acquired Tumor Cell Resistance.
Cancers (Basel)
December 2023
Department of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Franz-Josef-Strauß-Allee 11, 93053 Regensburg, Germany.
The concept of post-therapy metastatic spread, cancer repopulation and acquired tumor cell resistance (M-CRAC) rationalizes tumor progression because of tumor cell heterogeneity arising from post-therapy genetic damage and subsequent tissue repair mechanisms. Therapeutic strategies designed to specifically address M-CRAC involve tissue editing approaches, such as low-dose metronomic chemotherapy and the use of transcriptional modulators with or without targeted therapies. Notably, tumor tissue editing holds the potential to treat patients, who are refractory to or relapsing (r/r) after conventional chemotherapy, which is usually based on administering a maximum tolerable dose of a cytostatic drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!